Atypical hearing loss in women with breast cancer receiving adjuvant treatment

7Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

There are no reports of adjuvant treatments for early breast cancer causing hearing loss. Yet in this exploratory study 14/16 women who had received Fluorouracil, Epirubicin and Cyclophosphamide (FEC) chemotherapy regimen, 11 of whom also received endocrine treatment, had reduced hearing sensitivity, with 9/16 being atypical. It is not clear whether this finding is related to oestrogen reduction and/or ototoxicity but a more detailed investigation in this area is warranted given the large number of women with breast cancer who receive adjuvant treatments. © 2005 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Jenkins, V., Beveridge, H., Low, R., & Mitra, S. (2006). Atypical hearing loss in women with breast cancer receiving adjuvant treatment. Breast, 15(3), 447–450. https://doi.org/10.1016/j.breast.2005.06.005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free